Finn Patrick John

About Finn Patrick John

Finn Patrick John, commonly known as Patrick Finn, is President and Chief Operating Officer at Twist Bioscience Corp, a U.S.-listed company on Nasdaq focused on synthetic biology and DNA synthesis. His career reflects an effective blend of scientific training and commercial leadership, a profile well suited to deep-tech and life sciences businesses. At Twist, he first served as Vice President of Sales and Marketing from February 2015, then as Senior Vice President of Commercial Operations from December 2018, before moving into his current operating leadership role. That internal progression suggests a long-standing relationship with the company and deep familiarity with its commercial model, customer base, and growth priorities. Prior to joining Twist Bioscience, Patrick Finn was Vice President of Sales at Enzymatics Inc., a developer, manufacturer, and marketer of enzymes for molecular biology applications serving research and diagnostic markets. In that role, he led commercial activities across North America and Europe, contributing to top-line growth and the expansion of the company’s B2B customer base. His earlier career also includes positions of increasing responsibility in business development and product development at companies such as Agilent Technologies and Beckman Coulter Molecular Diagnostics, along with technical roles at Invitrogen and GE Healthcare/Amersham International. He has also served on scientific advisory boards, which reinforced his credibility at the intersection of science, product strategy, and commercialization. Academically, Finn holds a BSc in Chemistry from Heriot-Watt University and a PhD in Chemistry, specifically Nucleic Acid Chemistry, from the University of Southampton. That background aligns closely with his executive responsibilities in a company industrializing DNA synthesis and synthetic biology tools. At Twist, his leadership has likely supported commercial scaling, international market development, and the operational discipline needed to move advanced biotechnology products from platform to market. From a corporate governance perspective, he stands out as an execution-focused executive with strong commercial instincts, technical depth, and experience leading growth in science-driven businesses.